Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 284-286

  Atcheson, Bronwyn A ^a,b   Taylor, Paul J ^a,b   Kirkpatrick, Carl M J ^a   Duffull, Stephen B ^a   Mudge, David W ^b   Pillans, Peter I ^a,b   Johnson, David W ^b   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Free drug; Hypoalbuminemia; Mycophenolic acid; ROC curve

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SERUM ALBUMIN; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AREA UNDER CURVE; DRUG MONITORING; FEMALE; HUMANS; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY;

EID: 2542590879     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00011     Document Type: Article

References (16)

1. Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem. 1998;31:329-333.
2. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
3. Pillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporine concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001;34:77-81.
4. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003;25:137-157.
5. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
6. Verme CN. Determinations of free drug concentrations for clinical use. Am. Assoc Clin Chem Educ. 1992;13:7-15.
7. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-769.
8. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
9. Doumas B, Watson W, Biggs H. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87-96.
10. Atcheson B, Taylor PJ, Mudge DW, et al. Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet detection. J Chromatogr B. 2004;799:157-163.
11. Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem. 2002;39:173-183.
12. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19.
13. Gugler R, Azarnoff DL. Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet. 1976;1:25-35.
14. Bauer LA, Edwards WAD, Dellinger EP, et al. Importance of unbound phenytoin serum levels in head trauma patients. J Trauma. 1983;23:1058-1060.
15. Gal P, Oles KS, Baird WH. Phenytoin and carbamazepine serum protein binding in a geriatric patient population. Clin Pharmacokinet. 1984;9:92-93.
16. Boucher BA, Rodman JH, Jaresko GS, et al. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther. 1998;44:675-683.